Vivoryon Therapeutics NV (LTS:0R3M) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R3M Vivoryon Therapeutics NV LTS:0R3M
33 GF Score
Price €1.21
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0R3M vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Short Interest distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Short Interest falls into.


LTS:0R3M
33GF Score
Vivoryon Therapeutics NV LTS:0R3M
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
33GF Score

Get the complete analysis for LTS:0R3M

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price